Archive · 23 Jul 2025
Dr. Reddy's Q1 FY26: PAT Up 2%, Revenue Climbs 11%
Dr. Reddy's, a pharmaceutical company, announced its financial results for the first quarter of the fiscal year 2026.
They made a little bit more money, about 2% more than last year.
They also sold more products, with revenue going up 11%.
However, they didn't make as much profit from each sale as before.
The company's leader said things are going well, especially with certain medicines.
They also mentioned that it might get harder to sell one specific medicine in the US because of pricing issues.
Dr. Reddy's Q1 FY26 profit after tax (PAT) rose 2% YoY to Rs 1,417.8 crore.
Revenue from operations increased 11% YoY to Rs 8,545.2 crore.
Gross margin declined to 56.9% from 60.4% in the previous year's quarter.
GV Prasad noted double-digit growth, highlighting branded markets and Nicotine Replacement Therapy.
Pricing pressure on Lenalidomide in the US generics market is expected to intensify.
- Who
- Dr. Reddy's Laboratories Ltd.
- What
- Dr. Reddy's Q1 FY26 financial results were released.
- When
- The results were for the quarter ending June 30, 2025.
- Where
- Information not available.
- Why
- To inform investors and the public about the company's financial performance.
- PAT (Q1 FY26)
- Rs 1,417.8 crore
- PAT YoY Growth
- 2%
- Revenue (Q1 FY26)
- Rs 8,545.2 crore
- Revenue YoY Growth
- 11%
- Gross Margin
- 56.9%
- Previous Year's Gross Margin
- 60.4%
- Stock Close
- Rs 1,247.55